阴道上皮内瘤变的持续、进展与复发风险因素分析
回顾性分析1478例组织学确诊的VAIN患者,中位随访14个月,86.6%恢复正常,6.4%持续,3.5%进展,3.5%复发。VAIN 3进展为癌风险更高,切除治疗结局更优。HPV 16/56/59/43感染与持续相关,因宫颈病变行子宫切除史和HPV 56感染与进展相关,HPV 61感染与复发相关。
要点
- VAIN多可自然消退,但仍存在持续、复发及进展甚至恶变风险,建议长期随访。
- VAIN 3进展为癌风险较高,优先选择切除治疗。
- HPV 16、56、59、43感染与持续相关,HPV 56感染及因宫颈病变行子宫切除史与进展相关。
核心结论
- 多数VAIN患者可恢复正常,但仍存在持续、复发和进展风险,甚至恶变,推荐长期随访。
- VAIN 3患者进展为癌风险更高,切除治疗结局更优。
- HPV 16、56、59、43感染可能与持续风险增加相关,因宫颈病变行子宫切除史的患者倾向于进展。
研究设计与样本
- 回顾性队列研究,纳入四川大学华西第二医院五年期间组织学确诊的VAIN患者,随访至少6个月。
- 共1478例符合纳入标准,中位随访14个月(范围6-60个月)。
- 提取人口学、病史及诊治临床信息,结局包括正常化、持续、进展和复发,采用单因素和多因素分析评估风险因素。
主要发现
- 86.6%的患者VAIN正常化,6.4%持续,3.5%进展,3.5%复发。
- 24例(7.1%)VAIN 3患者和4例(0.8%)进展为癌,分别占癌变病例的85.7%和14.3%。
- VAIN 3患者接受切除治疗结局更优。
- 持续的风险因素为HPV 16、56、59和43感染;进展的风险因素为因宫颈病变行子宫切除史和HPV 56感染;复发的风险因素为HPV 61感染。
关键数值与推荐
- VAIN 3患者中7.1%进展为癌,占所有癌变病例的85.7%。
- 非VAIN 3患者中0.8%进展为癌,占所有癌变病例的14.3%。
临床怎么用
- 对VAIN患者应进行长期随访,监测持续、复发和进展。
- VAIN 3患者优先考虑切除治疗以改善结局。
- 对合并HPV 16、56、59、43感染或因宫颈病变行子宫切除史的患者加强风险监测。
局限性
- 回顾性研究设计,可能存在选择偏倚和信息偏倚。
- 中位随访14个月,随访时间较短,可能低估远期复发和进展风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: to profile patients with vaginal intraepithelial neoplasia (VAIN), to evaluate natural history and to identify risk factors for persistence, progression and recurrence. METHODS: At West China Second University Hospital, all patients with histologically confirmed VAIN over a five-year period with minimum follow-up of 6 months were retrospectively identified. Demographics, medical history and clinical information related to the diagnosis and treatment were extracted. Clinical outcomes included normalization, persistence, progression and recurrence. We evaluated risk factors by univariate and multivariate analyses. RESULTS: A total of 1478 patients fulfilled the inclusion criteria with a median follow-up of 14 months (range, 6-60 months). In 86.6% of patients, VAIN went into normalization, 6.4% persisted, 3.5% progressed and 3.5% recurred. Besides, 24 (7.1%) VAIN 3 patients and 4 (0.8%) progressed to cancer, accounting for 85.7% and 14.3% of cancer cases, respectively. VAIN 3 patients treated with excision yielded superior outcomes. Risk factors for persistence were HPV 16, 56, 59 and 43 infections, for progression were prior hysterectomy for cervical lesions and HPV 56 infection, for recurrence were HPV 61 infection. CONCLUSION: Although VAIN will regress in most patients, there are still risks of persistence, recurrence and progression, even malignancy. Therefore, a long-term follow-up is recommended. Patients with VAIN 3 are at higher risk of progressing to cancer and excision is preferred. HPV 16, 56, 59 and 43 infections might associate with an increased risk of persistence and patients with prior hysterectomy for cervical lesions tend to progress.
引用
- Ao M, Zheng D, Wang J, et al. Risk factors analysis of persistence, progression and recurrence in vaginal intraepithelial neoplasia. Gynecol Oncol. 2021. PMID: 34226020. doi:10.1016/j.ygyno.2021.06.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。